# US 2011/0301341 A1 · Modified organs and cells for xenotransplantation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0301341 A1
- Document ID: US20110301341A1
- Status: Published application
- Kind: A1
- Application number: 13/211,040
- Filed: 2011-08-16
- Published: 2011-12-08
- Earliest claimed: 2001-04-30
- Assignees: RBC Biotechnology, Inc.
- Inventors: Alex Zhu
- Web page: https://patentgrep.com/patent/US20110301341A1

## CPC

- A61K 35/18: Erythrocytes (haemoglobin A61K38/42)
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A01K 2217/075: inducing loss of function, i.e. knock out
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

It has been discovered that there are at least two significant antigens present on the cells of animal species such as pigs that elicit an immune or inflammatory response immediately upon implantation into humans or contact with human serum. The first is an α-galactosyl (Gal) epitope, for example, Galα(1->3)Galβ(1->4)GlcNac (linear B type 2) or Galα(1->3)Galβ(1->4)Glc (linear B type 6). The second is an N-glycolylneuraminic acid (NeuGc) structure. By eliminating these epitopes, preferably by genetically engineering the animal so that the epitope is either not produced or is greatly reduced. or by chemical or enzymatic treatment of the animal's cells to remove the epitopes, it is possible to produce organs, tissues and cells suitable for xenotransplantation into humans. Cells can be rendered even more compatible by genetically engineering the animal to express a human complement regulatory protein (inhibitor), such as CD59, on its cells, or to express an excess of a pig complement regulatory protein.

## Claims

### Claim at position 1

1-27. (canceled)

### Claim 28

A method for increasing the half-life of recombinant or non-human proteins comprising removing or reducing expression of NeuGc and/or Gal epitopes on the surface thereof.

### Claim 29 (depends on 28)

The method of claim 28 where the proteins are mouse, pig or goat or other non-human mammalian proteins or derived from non-human mammalian cell lines.

### Claim 30

Recombinant or non-human proteins having removed in whole or in part the NeuGc and/or Gal epitopes on the surface thereof.

### Claim 31 (depends on 30)

The proteins of claim 30 where the proteins are mouse, pig, goat or other non-human mammalian proteins or derived from non-human mammalian cell lines.
